Mavacoxib-d4
Product Specifications
UNSPSC Description
Mavacoxib-d4 is the deuterium labeled Mavacoxib. Mavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs[1].
Target Antigen
COX; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Immunology/Inflammation;Others
Field of Research
Inflammation/Immunology
Solubility
10 mM in DMSO
Smiles
O=S(C1=C([2H])C([2H])=C(N2N=C(C(F)(F)F)C=C2C3=CC=C(F)C=C3)C([2H])=C1[2H])(N)=O
Molecular Weight
389.36
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Hurst EA, et al. The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels. Vet Comp Oncol. 2019 Jun;17(2):194-207.|[3]Cox SR, et al. Population pharmacokinetics of mavacoxib in osteoarthritic dogs. J Vet Pharmacol Ther. 2011 Feb;34(1):1-11.
Shipping Conditions
Room temperature
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1426643-01 0.02 mg (E-Coli)
Recombinant Legionella pneumophila UPF0234 protein lpl1175 (lpl1175)
Ask
View Details MBS1426643-02 0.1 mg (E-Coli)
Recombinant Legionella pneumophila UPF0234 protein lpl1175 (lpl1175)
Ask
View Details